Another interesting target is the B-cell lymphoma-2 (BCL2) gene, an estrogen-responsive gene coding for an antiapoptotic protein overexpressed in approximately 80% of patients with HR+ BC [134]. This evidence concerns the gene BCL2 and breast cancer.